Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Dopamine is the most intensely studied monoaminergic neurotransmitter. Dopaminergic neurotransmission plays an important role in regulating several aspects of basic brain function, including motor, behavior, motivation, and working memory. To date, there are numerous positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracers available for targeting different steps in the process of dopaminergic neurotransmission, which permits us to quantify dopaminergic activity in the living human brain. Degeneration of the nigrostriatal dopamine system causes Parkinson’s disease (PD) and related Parkinsonism. Dopamine is the neurotransmitter that has been classically associated with the reinforcing effects of drug abuse. Abnormalities within the dopamine system in the brain are involved in the pathophysiology of attention deficit hyperactivity disorder (ADHD). Dopamine receptors play an important role in schizophrenia and the effect of neuroleptics is through blockage of dopamine D 2 receptors. This review will concentrate on the radiotracers that have been developed for imaging dopaminergic neurons, describe the clinical aspects in the assessment of neuropsychiatric disorders, and suggest future directions in the diagnosis and management of such disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101 · cited 2×
“The failure to observe the “high” with oral methylphenidate is likely to reflect the slower pharmacokinetics [76, 77, 85].”
BackgroundKapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 2×
“Neuroimaging holds promise for unveiling the neurobiological causes of ADHD and provides invaluable information for management of the disease.”
BackgroundImaging dopamine's role in drug abuse and addiction
Volkow, N. D., Fowler, J. S., Wang, G. J., Baler, R., & Telang, F. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.022 · Cited by 988
Volkow, N. D., Fowler, J. S., Wang, G., Hitzemann, R., Logan, J., Schlyer, D. J., Dewey, S. L., & Wolf, A. P. (1993) · Synapse · doi:10.1002/syn.890140210 · Cited by 924
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Ding, Y.-S., Sedler, M., Logan, J., Franceschi, D., Gatley, J., Hitzemann, R., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2015 · Cited by 916
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gatley, S. J., Hitzemann, R., Chen, A. D., Dewey, S. L., & Pappas, N. (1997) · Nature · doi:10.1038/386830a0 · Cited by 854
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Prefrontal Dopamine D1Receptors and Working Memory in Schizophrenia
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724 · cited 3×
“Dopamine D1 receptor 11C-NNC 112 (+)-5-(7-Benzofuranyl)-8-chloro-7-hydroxy3-methyl-2,3,4,5-tetrahydro-1H-3benzazepine Schizophrenia [71]”
BackgroundDopamine transporter density in patients with attention deficit hyperactivity disorder
Dougherty, D. D., Bonab, A. A., Spencer, T. J., Rauch, S. L., Madras, B. K., & Fischman, A. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04030-1 · Cited by 684 · cited 2×
“The first DAT imaging study was conducted in 6 adults with ADHD by using 123I-altropane SPECT, showing that the DAT levels in unmedicated patients were approximately 70% higher than those in controls [69].”
MethodSolanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677 · cited 1×
“Methylphenidate is considered as a first-line medication for ADHD in children and adults [86, 115].”
BackgroundDopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., Swanson, J. M., & Telang, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1575 · Cited by 605
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596 · cited 1×
“…receptor combined with low nonspecific binding to brain tissue not containing the receptor of interest; rapid permeation through the bloodbrain barrier permitting high access of tracers to receptors, as well as allowing high initial brain uptake and fast clearance of the activity from the brain.”
BackgroundVolkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575 · cited 1×
“Therefore, it is postulated that the initial uptake of these stimulant drugs into the brain, not their steadystate presence, is necessary for drug-induced reinforcement [76, 114].”
BackgroundKrause, K.-H., Dresel, S. H., Krause, J., Kung, H. F., & Tatsch, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01040-5 · Cited by 521 · cited 1×
“However, following studies with a variety of DAT markers have shown a much smaller increase even not reaching statistical significance than that found in the first study with 123I-altropane [38, 45, 64, 65, 70].”
ResultVolkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gatley, S. J., Gifford, A., Hitzemann, R., Ding, Y.-S., & Pappas, N. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1440 · Cited by 406 · cited 1×
“Mean sensitivity of 123I-FP-CIT scans for a clinical diagnosis of probable dementia with Lewy bodies was 77.7%, while the mean specificity for excluding non-Lewy body dementia was 90.4%, giving overall diagnostic accuracy of 85.7% [19, 43, 44, 94].”
BackgroundInfluentialResults from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · cited 1×
“18F-FMT O-[18F]-fluoromethyl-D-tyrosine Gene therapy for PD [30, 31]”
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344 · cited 1×
“18F-FMT O-[18F]-fluoromethyl-D-tyrosine Gene therapy for PD [30, 31]”
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., Ding, Y., Gatley, S. J., Gifford, A., Zhu, W., et al. (2002) · Synapse · doi:10.1002/syn.10038 · Cited by 321 · cited 3×
“Dopamine D2 receptor 11C-Raclopride 3,5-dichloro-N-{[(2S)-1-ethylpyrrolidin-2yl]methyl}-2-hydroxy-6[11C]methoxybenzamide Drug abuse [74–79] cocaine abuse [80, 81], methamphetamine abuse [82], opiate abuse [83], alcohol dependence [84], ADHD [85, 86], antipsychotics [48, 87–89]”
BackgroundDresel, S., Krause, J., Krause, K.-H., LaFougere, C., Brinkbäumer, K., Kung, H. F., Hahn, K., & Tatsch, K. (2000) · European Journal of Nuclear Medicine · doi:10.1007/s002590000330 · Cited by 278
High Midbrain [ 18 F]DOPA Accumulation in Children With Attention Deficit Hyperactivity Disorder
Ernst, M., Zametkin, A. J., Matochik, J. A., Pascualvaca, D., Jons, P. H., & Cohen, R. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1209 · Cited by 256 · cited 2×
“investigated the integrity of presynaptic dopaminergic function in children with ADHD through the use of 18F-DOPA PET and found a 48% increase in DOPA decarboxylase activation in the right midbrain in ADHD children compared with normal controls [27].”
BackgroundSPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder
Krause, J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.611 · Cited by 110
Shi, J., Zhao, L.-Y., Copersino, M. L., Fang, Y.-X., Chen, Y., Tian, J., Deng, Y., Shuai, Y., Jin, J., & Lu, L. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.09.042 · Cited by 108 · cited 2×
“Furthermore, the subjects with methadone maintenance treatment showed significant decreases of DAT uptake function in the bilateral putamen in comparison to the prolonged abstinence subjects [32].”
ResultKrause, K.-H., Dresel, S. H., Krause, J., Kung, H. F., Tatsch, K., & Ackenheil, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002821 · Cited by 88 · cited 1×
“DAT seems to be elevated in nonsmoking ADHD patients suffering from the purely inattentive subtype of ADHD as well as in those with the combined or purely hyperactive/impulsive subtype [63, 68].”
BackgroundKrause, J., la Fougere, C., Krause, K.-H., Ackenheil, M., & Dresel, S. H. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0602-x · Cited by 84 · cited 1×
“It has shown that ADHD patients with poor response to methylphenidate had a low primary DAT availability, whereas most of patients with high DAT availability exhibited good clinical response to methylphenidate [66, 67].”
BackgroundLarisch, R., Sitte, W., Antke, C., Nikolaus, S., Franz, M., Tress, W., & M??ller, H.-W. (2006) · Nuclear Medicine Communications · doi:10.1097/00006231-200603000-00010 · Cited by 58
la Fougère, C., Krause, J., Krause, K.-H., Josef Gildehaus, F., Hacker, M., Koch, W., Hahn, K., Tatsch, K., & Dresel, S. (2006) · Nuclear Medicine Communications · doi:10.1097/01.mnm.0000230077.48480.68 · Cited by 57 · cited 1×
“It has shown that ADHD patients with poor response to methylphenidate had a low primary DAT availability, whereas most of patients with high DAT availability exhibited good clinical response to methylphenidate [66, 67].”
Background
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
Dalsgaard, S., Mortensen, P. B., Frydenberg, M., Maibing, C. M., Nordentoft, M., & Thomsen, P. H. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.06.004 · Cited by 121
“In ADHD, there is increased density of presynaptic dopamine transporters (DAT) and dopamine receptors play a key role in schizophrenia [64].”
BackgroundHutson, P. H., Tarazi, F. I., Madhoo, M., Slawecki, C., & Patkar, A. A. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.005 · Cited by 31
“Alterations in dopaminergic activity in these pathways are implicated in multiple disorders, including ADHD, narcolepsy, bipolar disorder, drug abuse, MDD, and schizophrenia (Wisor et al., 2001; Miklowitz & Johnson, 2006; Heal et al., 2009; El Mansari et al., 2010; Shen et al., 2012).”
Background
Metadata
- Authors
- Shen, L.-H., Liao, M.-H., & Tseng, Y.-C.
- Venue
- Journal of Biomedicine and Biotechnology
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-14
- ISSN
- 1110-7243 (ISSN-L)
- 1110-7251
- OpenAlex
- W2076510166
- Cited by
- 86
- References
- 31
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.